We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

EKF Diagnostics

Manufactures analysers for the measurement of glucose, lactate, hemoglobin, hematocrit and HbA1c for GP surgeries, ph... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Studies Validate Early-Stage Test for Progressive Diabetic Kidney Disease

By LabMedica International staff writers
Posted on 02 Jun 2014
Print article
Image: The sTNFR1 diagnostic test kit—greater accuracy for early risk-prediction of advanced diabetic kidney disease and associated renal decline (Photo courtesy of EKF Diagnostics).
Image: The sTNFR1 diagnostic test kit—greater accuracy for early risk-prediction of advanced diabetic kidney disease and associated renal decline (Photo courtesy of EKF Diagnostics).
Scientific evidence from independent clinical validation studies has confirmed that novel sTNFR1/2 biomarkers can predict end-stage renal disease well in advance.

EKF Diagnostics (Cardiff, UK) has confirmed the growing weight of evidence as validation that soluble TNF Receptors 1 and 2 (sTNFR1/2) are strong biomarkers of progressive diabetic kidney disease (DKD). EKF affirms that the markers can be reliably used as diagnostic tests to predict end-stage renal disease (ESRD)—one of the greatest mortality risks in diabetics—up to 10 years in advance.

The evidence also supports and validates EKF’s sTNFR1 test—a microtitre plate, ELISA-based assay using monoclonal antibodies. The test accurately and reliably detects circulating levels of sTNFR1 in patient samples in just a few hours with minimal interference and cross-reactivity. The test is easy-to-use with standard laboratory equipment and requires only 50 µL of blood serum or plasma.

Since signing an exclusive license agreement in 2012 for this novel kidney biomarker technology with Joslin Diabetes Center (Boston, MA, USA), EKF Diagnostics has worked with Joslin and other diabetic research centers to further validate clinical utility and develop its sTNFR1 test kit. Both sTNFR1/2 biomarkers have consistently been shown to predict risk of advanced DKD and associated renal decline with greater accuracy than other available clinical tests.

Resulting from this joint work, several important studies have now been published, independently corroborating the original research by Joslin, which reported the strong association of elevated sTNFR1/2 levels with the subsequent development of advanced DKD in Type 1 and Type 2 diabetic patients. The newly published data from research centers SURDIAGNE Study Group (France) and FinnDiane Study Group (Finland) add to the expanding data set underpinning the value of sTNFR1/2 biomarkers. Independently, work published from PIVUS and ULSAM Study Groups (Sweden) confirm and extend the findings to a community-based setting and to nondiabetic patients, supporting the relevance of these biomarkers for kidney damage and dysfunction.

Additional highlights include: For patients with sTNFR1 levels in the highest quartile, the risk of progression to ESRD was nearly 80% in 12 years; Findings not only confirm the deleterious role of TNFR1 on kidney function but also point to a clear association with all-cause mortality. Circulating levels of sTNFR1 are independently associated with incidence of ESRD.

Accurate and early identification of patients at the highest risk of progression from DKD to ESRD will enable early initiation of protective therapies with subsequent reduction in costs and improved patient outcomes. “The growing volume of newly published high-impact scientific papers certainly serves to highlight the growing awareness and value of sTNFR1/2 as biomarkers of progressive DKD,” commented Julian Baines, CEO, EKF Diagnostics; “Currently there is no accepted gold standard for the diagnosis and progression of DKD. That said, our sTNFR1 test has already been shown to add greatly to information provided by standard clinical criteria, allowing clinicians to pinpoint patients who need the most care as early as possible.”

Related Links:

EKF Diagnostics


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.